(NASDAQ: EVAX) Evaxion A's forecast annual revenue growth rate of 167.09% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Evaxion A's revenue in 2025 is $3,176,000.On average, 1 Wall Street analysts forecast EVAX's revenue for 2025 to be $802,204,664, with the lowest EVAX revenue forecast at $802,204,664, and the highest EVAX revenue forecast at $802,204,664. On average, 1 Wall Street analysts forecast EVAX's revenue for 2026 to be $4,209,995,345, with the lowest EVAX revenue forecast at $4,209,995,345, and the highest EVAX revenue forecast at $4,209,995,345.
In 2027, EVAX is forecast to generate $21,410,021,336 in revenue, with the lowest revenue forecast at $21,410,021,336 and the highest revenue forecast at $21,410,021,336.